Genmab A/S is paying $8 billion to acquire Merus NV, gaining rights to the latter’s phase III-stage petosemtamab, a ...

Antibodies that bind to sugars on the surface of cancer cells, rather than to proteins, have not yielded satisfactory results so far due to their low binding affinity. However, scientists at the ...

Eli Lilly and Co.’s oral selective estrogen receptor degrader (SERD) imlunestrant has been approved by the U.S. FDA for ...

Youthbio Therapeutics Inc. has held a successful INTERACT meeting with the FDA for its lead Alzheimer’s candidate, YB-002.

Boehringer Ingelheim Pharma GmbH & Co KG has advanced a novel T-cell engager resulting from a collaboration with Numab ...

The U.S. FDA released a trio of draft guidances to help sponsors in developing and monitoring cell and gene therapies, as ...

Rakuten Medical Inc. is advancing a pipeline of solid tumor therapeutics built on its Alluminox platform worldwide, having ...

Coronary artery bypass graft (CABG) surgery remains the gold standard treatment for patients with severe atherosclerosis, but ...

The Human Cell Atlas project has delivered a fresh tranche of data mapping fibroblasts in healthy and diseased skin and ...

Nailing down what Oppenheimer analyst Jay Olson characterized as “a trifecta,” Immuneering Corp. unveiled positive updated ...

After a phase III stumble, Acadia Pharmaceuticals Inc. will drop development of ACP-101, intranasal carbetocin, to treat ...

The threat of tariffs on imports of branded drugs is about to be realized after U.S. President Donald Trump announced a 100% ...